Management Quality -- 7/10
FMS management scores a 7/10 -- reflecting a competent, transparent team executing a credible turnaround
under CEO Helen Giza (since Oct 2023). The FME25 savings program over-delivered dramatically (EUR 804M
cumulative vs. original EUR 450M target), net leverage was reduced from 3.4x to 2.5x, and FY2025 operating
income grew 27% at constant currency -- hitting the top end of guidance. However, the core organic volume
growth story remains unproven: U.S. same market treatment growth has stalled near flat for 2+ years, and the
2%+ target has been repeatedly deferred. Care Enablement margin missed the 8% floor on a full-year basis.
A score of 7 reflects good management with execution gaps on the most important metric.
Weight: 20%
CEO
Helen Giza (Oct 2023)
Former CFO of DaVita; deep dialysis expertise | Stable tandem with CFO Fischer
Promise Delivery
8/10 met or exceeded
1 partially met (CE margin), 1 delayed (US volume growth)
FME25 Savings
EUR 804M cumulative
Original target EUR 450M; upgraded 3x and still over-delivered
Net Leverage
2.5x (from 3.4x)
Target band 2.5-3.0x achieved; steady quarterly progression
Leadership team
Helen Giza -- CEO and Chair of Management Board (Oct 2023)
Former CFO of DaVita -- deep dialysis industry expertise and financial discipline. Detail-oriented
on calls, comfortable with granular KPIs (referral trends, missed treatments, catheter rates).
Consistently direct about what she can and cannot control. Projects strong operational credibility.
The Giza-Fischer tandem has been stable for ~2 years with no turnover signals. Oversees both the
FME25+ transformation and the FME Reignite 2030 strategy.
Martin Fischer -- CFO (since 2023)
Internal promotion; disciplined capital allocator. Precise on financial bridge items and rarely
hedges excessively. Provides explicit headwind/tailwind building blocks each quarter, allowing
analysts to reconstruct the bridge. Managed guidance through volatile periods including the Change
Healthcare cyber incident and severe flu season impacts. Strong complementary skill set to Giza.
Promise vs. delivery tracker (10 completed, 2 ongoing/new)
| When Promised | Promise | Evidence | Grade |
|---|---|---|---|
| 2023 CMD | FME25 cumulative savings EUR 750M+ | Delivered EUR 804M cumulative by end 2025; upgraded target 3x (EUR 450M -> EUR 650M -> EUR 750M). EUR 238M in 2025 alone vs EUR 220M target. | EXCEEDED |
| 2023 CMD | Group OI margin 10-12% by 2025 | FY 2025 group OI margin excl. special items: 11.3%. Q4 2025 hit 13.9%. Upper half of band. | MET |
| 2023 CMD | Care Delivery margin 10-14% by 2025 | FY 2025 CD margin: 11.8%. Q3 hit 12.3%, Q4 hit 16.4% (TDAPA-boosted). Middle of band. | MET |
| 2023 CMD | Care Enablement margin 8-12% by 2025 | FY 2025 CE margin: 6.0%. Touched 8.7% in Q2 but FY average below 8% floor. China and FX headwinds. | PARTIAL |
| Q3 2024 | U.S. same market treatment growth 2%+ | FY 2025 ~flat (0.1% in Q3). Mortality still elevated. Target pushed to over time -- 2026 guided flat again. | DELAYED |
| Mid-2025 | Net leverage ratio 2.5-3.0x | Leverage improved 3.4x (end 2022) to 2.5x (end 2025). Steady quarterly progression. | MET |
| June 2025 | EUR 1B share buyback program | First tranche EUR 600M commenced Aug 2025; EUR 586M repurchased in 2025 (4.8% of share capital). | ON TRACK |
| Feb 2025 | 2025 OI growth: high teens to high 20s % | FY 2025 OI growth of 27% at CC. Hit top end of range. Confirmed across all interim calls. | MET (top) |
| Feb 2025 | 2025 Revenue: positive to low single-digit growth | Organic revenue growth 8.2% for FY 2025; upper end driven by VBC revenue recognition. | MET |
| 2024-2025 | 5008X / HDF U.S. rollout | Soft launch completed H2 2025; 30 clinics / 600 machines. Large-scale rollout commenced early 2026. | ON TRACK |
| 2024 | VBC breakeven by 2025 | VBC OI: positive EUR 3M in FY 2025 vs loss of EUR 28M in FY 2024. First year of breakeven. | MET |
| Feb 2026 | 2026 OI: broadly flat (mid-single-digit +/- range) | Margin range 10.5-12%. Transparent on TDAPA phase-out headwind (EUR 150-200M) and investments (EUR 100-150M). | NEW |
8 of 10 completed targets met or exceeded; 1 partially met (CE margin missed 8% floor on full-year basis);
1 delayed (U.S. volume growth -- the core organic growth KPI -- has stalled near flat for 2+ years).
This is a strong execution record given external headwinds (flu severity, FX, China regulatory changes).
Source: Daloopa, earnings call transcripts Q3 2024 - Q4 2025.
Qualitative assessment
Communication Quality -- 8/10
Giza is notably transparent about what is and is not working. She clearly sized the phosphate binder
benefit (EUR 220M in 2025), broke out the catheter lock TDAPA contribution (EUR 90M), and acknowledged
softer volumes without hiding behind qualifiers. Management provides explicit headwind/tailwind building
blocks each quarter. Guidance was set and confirmed without narrowing -- but results landed at the top
end, suggesting conservative initial guidance with strong execution. One concern: the 2%+ U.S. same
market treatment growth target has been repeated for 6+ quarters without being achieved.
Operational Execution -- 8/10
FME25+ savings consistently over-delivered: original EUR 450M target expanded to EUR 804M cumulative.
Revenue cycle management improvements visibly reducing implicit price concessions. Patient inflow
trends improving -- strongest Q2 since 2020; 5 consecutive months of improving referrals (as of
Q2 2025). Vaccination rates 34% above prior year; antimicrobial catheter adoption at 84% of eligible
patients. Managed through Change Healthcare cyber incident, severe flu season, FX headwinds, and
China regulatory disruption.
Capital allocation assessment -- 8/10
Deleveraging -- disciplined
Reduced net leverage from 3.4x to 2.5x in 3 years while simultaneously returning capital to
shareholders. Steady quarterly progression through the target band. Strong cash generation:
EUR 2.7B operating cash flow in 2025 with FCF/revenue of 9.1%. Balance sheet risk is now minimal
with leverage at the low end of the target band.
Share repurchases -- EUR 1B program
EUR 1B buyback accelerated ahead of original schedule. First tranche (EUR 600M) commenced Aug 2025;
EUR 586M repurchased in 2025 representing 4.8% of share capital. Second tranche (EUR 414M) initiated
Jan 2026. Dividend maintained with 3% increase (33% payout ratio). Demonstrates alignment with
shareholder interests.
Portfolio rationalization
Reduced international footprint from 49 to 34 countries -- demonstrates willingness to exit
underperforming markets. Announced ~100 U.S. clinic closures for 2026, showing discipline in
rationalizing underperformers rather than chasing scale. CapEx discipline maintained within
EUR 500M-1B framework.
Strategic investment -- 5008X/HDF and VBC
5008X/HDF rollout is the right strategic bet -- CONVINCE trial data supports mortality reduction
and differentiates vs. DaVita. Large-scale rollout targeting ~20% of installed base in 2026 with
7,200 nurses being trained. VBC carve-out into separate segment improves transparency. VBC turned
breakeven (EUR 3M positive) in FY2025 vs EUR 28M loss in FY2024.
Red flags check
| Flag | Status | Detail |
|---|---|---|
| Frequent guidance misses | NO | Consistently met or beat guidance across all 6 quarters reviewed |
| CEO/CFO turnover | NO | Giza-Fischer tandem stable since Oct 2023; no turnover signals |
| TDAPA reliance in 2025 | WATCH | Phosphate binders + catheter lock contributed ~EUR 310M in 2025 -- real cash flows but flatters the margin trajectory |
| Persistent special items | MILD | Special items run EUR 50-111M per quarter over 3-year transformation; expected to wind down by end-2027 |
| US volume growth stalled | MILD | 2%+ SMTG reiterated for 6 quarters without delivery; management now avoids time-stamping the target |
| Deflection on tough questions | NO | Giza directly addresses volume weakness, TDAPA phaseout, ACA, and China questions |
| Balance sheet risk | NO | Leverage at low end of target band (2.5x); EUR 2.7B OCF; FCF/revenue 9.1% |
| Misaligned incentives | NO | Buyback + dividend increases suggest alignment; no unusual insider selling flagged |
Strengths and concerns
Strengths
1. FME25 savings dramatically over-delivered. EUR 804M cumulative vs. original
EUR 450M target -- upgraded 3 times and still beat the final target. EUR 238M in 2025 alone vs.
upgraded EUR 220M target. This is the hallmark of a team that under-promises and over-delivers
on controllable items.
2. Hit top end of 2025 OI guidance. 27% OI growth at constant currency in a challenging environment with flu severity, FX headwinds, and China disruption. Conservative initial guidance with strong execution -- the right pattern.
3. Transparent, detail-rich communication. Explicit building blocks with EUR-denominated buckets for headwinds and tailwinds. Giza directly addresses volume weakness and TDAPA dependency without deflection. Fischer precise on financial bridge items.
4. Disciplined capital allocation. Deleveraged 3.4x to 2.5x while returning capital. EUR 1B buyback accelerated. Portfolio rationalized (49 to 34 countries, ~100 U.S. clinic closures). CapEx discipline maintained.
5. Strategic positioning is differentiated. 5008X/HDF rollout backed by CONVINCE trial data. VBC turned breakeven. Both create long-term competitive moats vs. DaVita.
2. Hit top end of 2025 OI guidance. 27% OI growth at constant currency in a challenging environment with flu severity, FX headwinds, and China disruption. Conservative initial guidance with strong execution -- the right pattern.
3. Transparent, detail-rich communication. Explicit building blocks with EUR-denominated buckets for headwinds and tailwinds. Giza directly addresses volume weakness and TDAPA dependency without deflection. Fischer precise on financial bridge items.
4. Disciplined capital allocation. Deleveraged 3.4x to 2.5x while returning capital. EUR 1B buyback accelerated. Portfolio rationalized (49 to 34 countries, ~100 U.S. clinic closures). CapEx discipline maintained.
5. Strategic positioning is differentiated. 5008X/HDF rollout backed by CONVINCE trial data. VBC turned breakeven. Both create long-term competitive moats vs. DaVita.
Concerns
1. U.S. volume growth is the core problem. Same market treatment growth has stalled
near flat for 2+ years. The 2%+ target has been repeated for 6 quarters without delivery. 2026 is
guided flat again. For a dialysis company, volume is the long-term value driver -- and this metric
remains unproven under current management.
2. Care Enablement margin missed the floor. FY 2025 CE margin of 6.0% vs. 8-12% target band. Touched 8.7% in Q2 but fell short on a full-year basis due to China headwinds and FX transaction drag. More than quadrupled from ~2% base, but the miss is real.
3. Heavy TDAPA reliance in 2025. Phosphate binders + catheter lock contributed ~EUR 310M in 2025 -- significantly above original assumptions. These are real cash flows but they flatter the margin trajectory. TDAPA is phasing out, creating EUR 150-200M headwind in 2026.
4. 2026 is a transition year. OI guided broadly flat after 3 years of transformation. The transition year narrative needs to convert into actual growth by 2027. TDAPA phase-out plus EUR 100-150M in strategic investments create a demanding setup.
5. Persistent special items. EUR 50-111M per quarter over a 3-year transformation period. These are real transformation costs but the persistence of special items over 3 years warrants monitoring. Expected to wind down by end-2027.
2. Care Enablement margin missed the floor. FY 2025 CE margin of 6.0% vs. 8-12% target band. Touched 8.7% in Q2 but fell short on a full-year basis due to China headwinds and FX transaction drag. More than quadrupled from ~2% base, but the miss is real.
3. Heavy TDAPA reliance in 2025. Phosphate binders + catheter lock contributed ~EUR 310M in 2025 -- significantly above original assumptions. These are real cash flows but they flatter the margin trajectory. TDAPA is phasing out, creating EUR 150-200M headwind in 2026.
4. 2026 is a transition year. OI guided broadly flat after 3 years of transformation. The transition year narrative needs to convert into actual growth by 2027. TDAPA phase-out plus EUR 100-150M in strategic investments create a demanding setup.
5. Persistent special items. EUR 50-111M per quarter over a 3-year transformation period. These are real transformation costs but the persistence of special items over 3 years warrants monitoring. Expected to wind down by end-2027.
Score rationale
7/10. This is a competent, transparent management team executing a credible turnaround.
Giza has done a strong job on cost transformation (EUR 804M FME25 savings vs. EUR 450M original target),
capital allocation (3.4x to 2.5x leverage, EUR 1B buyback), and strategic positioning (5008X/HDF, VBC
breakeven). Communication quality is high -- explicit building blocks, direct acknowledgment of weaknesses,
conservative guidance with strong execution.
Why not 8+: (1) U.S. same market treatment growth -- the core organic growth KPI for a dialysis company -- has stalled near flat for 2+ years with the 2%+ target repeatedly deferred; (2) Care Enablement margin missed the 8% floor on a full-year basis; (3) 2025 margins were meaningfully flattered by ~EUR 310M in TDAPA benefits now phasing out; (4) 2026 is guided flat on OI -- after 3 years of transformation, the transition year narrative needs to convert into growth; (5) persistent special items over a 3-year period.
What would move this to 8+: U.S. same market treatment growth reaching 2%+ sustained (the single most important signal). Care Enablement margin entering and holding the 8-12% target band on a full-year basis. 2026 OI landing at or above the top end of the flat guidance range despite TDAPA phase-out. Special items declining meaningfully as FME25+ winds down. If the volume story finally inflects, this team has earned the benefit of the doubt on everything else.
Why not 8+: (1) U.S. same market treatment growth -- the core organic growth KPI for a dialysis company -- has stalled near flat for 2+ years with the 2%+ target repeatedly deferred; (2) Care Enablement margin missed the 8% floor on a full-year basis; (3) 2025 margins were meaningfully flattered by ~EUR 310M in TDAPA benefits now phasing out; (4) 2026 is guided flat on OI -- after 3 years of transformation, the transition year narrative needs to convert into growth; (5) persistent special items over a 3-year period.
What would move this to 8+: U.S. same market treatment growth reaching 2%+ sustained (the single most important signal). Care Enablement margin entering and holding the 8-12% target band on a full-year basis. 2026 OI landing at or above the top end of the flat guidance range despite TDAPA phase-out. Special items declining meaningfully as FME25+ winds down. If the volume story finally inflects, this team has earned the benefit of the doubt on everything else.
Data sourced from Daloopa and earnings call transcripts Q3 2024 - Q4 2025.